View a complete list of publications for Dr. Green

Delivery of radionuclides to malignant cells

Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur DS, Gopal AK, Hamlin DK, Press OW. Pretargeted Radioimmunotherapy for B-cell Lymphomas. Clinical Cancer Research 13 (18 Pt 2):5598s-5603s, 2007.

Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur DS, Fisher DR, Rajendran JG, Gopal AK, Park SI, Press OW. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood 114(6): 1226-1235, 2009. PMCID: PMC2723017

Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, Wilbur DS, Lin Y, Fisher DR, Kenoyer AL, Frayo SL, Gopal AK, Orozco JJ, Gooley TA, Wood BL, Bensinger WI, Press OW. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Research 74(4):1179-1189, 2014. PMCID: PMC3970848.

Green DJ, Frayo S, Lin Y, Wilbur DS, Hamlin DK, Fisher DR, Frost SHL, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, Orcutt KD, Wittrup KD, Press OW. Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B cell cancers. Cancer Research 2016 (accepted- with minor revisions).

Alpha emitter ²¹¹At-conjugated monoclonal antibodies in the treatment of hematological malignancies

Orozco JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides MD, Green DJ, Gopal AK, Press OW, Pagel JM. Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood 121(18):3759-3767, 2013. PMCID: PMC3643772.

Miller BW, Frost SH, Frayo SL, Kenoyer AL, Santos E, Jones JC, Green DJ, Hamlin DK, Wilbur DS, Fisher DR, Orozco JJ, Press OW, Pagel JM, Sandmaier BM. Quantitative Single-Particle Digital Autoradiography with α-Particle Emitters for Targeted Radionuclide Therapy using the iQID Camera. Medical Physics 42(7): 4094-4105, 2015.

Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur DS, Balkin ER, Lin Y, Miller BW, Frost SHL, Gopal AK, Orozco JJ, Gooley TA, Laird KL, Till BG, Back TA, Sandmaier BM, Pagel JM, Press OW. 211At conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood 125(13):2111-2119, 2015. PMCID: PMC4375108.

Autologous stem cell transplant for patients with multiple myeloma

Bensinger WI, Green DJ, Burwick N, Becker PS. A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma. Bone Marrow Transplantation 49(4):492-495, 2014.

Green DJ, Bensinger WI, Holmberg LA, Gooley T, Till BG, Budde LE, Pagel JM, Frayo SL, Roden JE, Hedin L, Press OW, Gopal AK. Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplantation doi: 10.1038/bmt.2016.123. [Epub ahead of print]. 2016

Becker PS, Gooley TA, Green DJ, Burwick N, Kim T, Kojouri K, Inoue Y, Moore D, Nelli E, Dennie T, Bensinger WI. A phase 2 study of Bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone (BCDD) for newly diagnosed multiple myeloma. Blood Cancer Journal 2016 May 13;6:e422. doi: 10.1038/bcj.2016.31

Bensinger WI, Becker PS, Gooley TA, Chauncey TR, Maloney DG, Gopal AK, Green DJ, Press OW, Lill M, Ifthikharuddin JJ, Holmberg LA, Phillips GL. A Randomized Study of Melphalan 200 mg/m2 v. 280 mg/m2 as a Preparative Regimen for Patients with Multiple Myeloma undergoing Autologous Stem Cell Transplantation. Bone Marrow Transplantation 51(1):67-71, 2016.

Alpha emitter ²¹³Bi-conjugated monoclonal antibody therapy to treat hematological malignancies

Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood 116(20): 4231-4239, 2010. PMCID: PMC2993626.

Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW. Anti-CD45 pretargeted radioimmunotherapy using 213Bi: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood 118:703-11, 2011. PMCID: PMC3142907.

β-emitter radionuclides in the management of hematological malignancy

Nemecek ER, Green D (Co-first Author), Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack L, Pantelias A, Hedin N, Rajendran J, Wilbur DS, Nilsson R, Sandberg B, Press OW. Extracorporeal adsorption therapy: A method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies in a non-human primate model. Cancer Biotherapy & Radiopharmaceuticals 23(2): 181-191, 2008.

Pagel JM, Orgun N, Hamlin DK, Wilbur DS, Gooley TA, Gopal AK, Park SI, Green DJ, Lin Y, Press OW. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 113:4903-13, 2009. PMCID: PMC2686140

Orozco JJ, Balkin ER, Kenoyer AL, Hamlin DK, Wilbur DS, Fisher DR, Hylarides MD, Shadman M, Green DJ, Gopal AK, Press OW, Pagel JM. Anti-CD45 Radioimmunotherapy with 90Y but not 177Lu is Effective Treatment in a Syngeneic Murine Leukemia Model. PLOS ONE 2;9(12):e113601, 2014. PMCID: PMC4252056.

Frost SH, Frayo SL, Miller BW, Orozco JJ, Booth G, Hylarides MD, Lin Y, Green DJ, Gopal AK, Pagel JM, Bäck T, Fisher DR, Press OW. Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models. PLoS ONE 10(3):e0120561, 2015